热门资讯> 正文
葛兰素史克-维尔生物技术公司的新冠肺炎药物对奥米克隆变种仍然有效
2021-12-02 15:40
02:35 AM EST, 12/02/2021 (MT Newswires) -- GlaxoSmithKline (GSK.L) and Vir Biotechnology said Thursday that their COVID-19 drug, sotrovimab, retained its neutralizing activity against the key mutations of the new omicron variant, citing pre-clinical data.
Pseudo-virus testing showed that the antibody therapy continues to demonstrate activity against all tested variants of concern and interest as defined by the World Health Organization. Clinical data also showed that a single dose of sotrovimab reduced the risk of hospitalization and death by 79% in high-risk adults with symptomatic COVID-19.
The companies are conducting in vitro pseudo-virus testing to confirm the effect of sotrovimab in addressing all the mutations of omicron, with an update expected by the end of 2021.
GlaxoSmithKline shares increased more than 1% on Wednesday's close.
Price (GBP): £1541.20, Change: £+16.20, Percent Change: +1.06%
